• 1
    Somers EC, Thomas SL, Smeeth L, Schoonen WM, Hall AJ. Incidence of systemic lupus erythematosus in the United Kingdom, 1990–1999. Arthritis Rheum 2007; 57: 6128.
  • 2
    Cooper G, Gilbert K, Greidinger E, James J, Pfau J, Reinlib L, et al. Recent advances and opportunities in research on lupus: environmental influences and mechanisms of disease. Cien Saude Colet 2009; 14: 186576.
  • 3
    Khamashta MA. Systemic lupus erythematosus and pregnancy. Best Pract Res Clin Rheumatol 2006; 20: 68594.
  • 4
    Ostensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8: 209.
  • 5
    Neri F, Chimini L, Bonomi F, Filippini E, Motta M, Faden D, et al. Neuropsychological development of children born to patients with systemic lupus erythematosus. Lupus 2004; 13: 80511.
  • 6
    Ross G, Sammaritano L, Nass R, Lockshin M. Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med 2003; 157: 397402.
  • 7
    Askanase AD, Izmirly PM, Katholi M, Mumtaz J, Buyon JP. Frequency of neuro-psychiatric dysfunction in anti-SSA/SSB exposed children with and without neonatal lupus. Lupus 2010; 19: 3006.
  • 8
    McAllister DL, Kaplan BJ, Edworthy SM, Martin L, Crawford SG, Ramsey-Goldman R, et al. The influence of systemic lupus erythematosus on fetal development: cognitive, behavioral, and health trends. J Int Neuropsychol Soc 1997; 3: 3706.
  • 9
    Lahita RG. Systemic lupus erythematosus: learning disability in the male offspring of female patients and relationship to laterality. Psychoneuroendocrinology 1988; 13: 38596.
  • 10
    Urowitz MB, Gladman DD, MacKinnon A, Ibanez D, Bruto V, Rovet J, et al. Neurocognitive abnormalities in offspring of mothers with systemic lupus erythematosus. Lupus 2008; 17: 55560.
  • 11
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 12
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 13
    Benediktsson R, Calder AA, Edwards CR, Seckl JR. Placental 11 β-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf) 1997; 46: 1616.
  • 14
    Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996; 87: 1638.
  • 15
    Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol 1998; 25: 10327.
  • 16
    Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika 1986; 73: 7514.
  • 17
    StataCorp. Stata statistical software: release 11. College Station (TX): StataCorp; 2009.
  • 18
    Aylward GP. Cognitive and neuropsychological outcomes: more than IQ scores. Ment Retard Dev Disabil Res Rev 2002; 8: 23440.
  • 19
    Ornstein M, Ohlsson A, Edmonds J, Asztalos E. Neonatal follow-up of very low birthweight/extremely low birthweight infants to school age: a critical overview. Acta Paediatr Scand 1991; 80: 7418.
  • 20
    Behan WM, Behan PO, Geschwind N. Anti-Ro antibody in mothers of dyslexic children. Dev Med Child Neurol 1985; 27: 53840.
  • 21
    Behan P, Geschwind N. Dyslexia, congenital anomalies, and immune disorders: the role of the fetal environment. Ann N Y Acad Sci 1985; 457: 138.
  • 22
    Hirvikoski T, Nordenstrom A, Lindholm T, Lindblad F, Ritzen EM, Wedell A, et al. Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J Clin Endocrinol Metab 2007; 92: 5428.
  • 23
    Bramham K, Thomas M, Nelson-Piercy C, Khamashta M, Hunt BJ. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011; 117: 694851.
  • 24
    Marder W, McCune WJ. Advances in immunosuppressive therapy. Semin Respir Crit Care Med 2007; 28: 398417.
  • 25
    DeWitte DB, Buick MK, Cyran SE, Maisels MJ. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr 1984; 105: 6258.
  • 26
    Cote CJ, Meuwissen HJ, Pickering RJ. Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr 1974; 85: 3248.
  • 27
    Norgard B, Pedersen L, Christensen LA, Sorensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102: 140613.
    Direct Link:
  • 28
    Matalon ST, Ornoy A, Lishner M. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol 2004; 18: 21930.
  • 29
    Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007; 79: 696701.
  • 30
    Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 917.
  • 31
    Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004; 99: 65661.
  • 32
    Shim L, Eslick GD, Simring AA, Murray H, Weltman MD. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis 2011; 5: 2348.
  • 33
    Armenti VT. Immunosuppression and teratology: evolving guidelines [letter]. J Am Soc Nephrol 2004; 15: 275960.
  • 34
    Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2002; 65: 24061.
  • 35
    De Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006; 101: 13902.
  • 36
    Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 90415.
  • 37
    Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 6426.
  • 38
    Gayed M, Toescu V, Leone F, Khamashta M, Gordon C. Outcome of children born to mothers with SLE. Rheumatology (Oxford) 2011; 50 Suppl: 110.
  • 39
    Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005; 52: 51421.
  • 40
    Jain V, Gordon C. Managing pregnancy in inflammatory rheumatological diseases. Arthritis Res Ther 2011; 13: 206.
  • 41
    Blackman JA, Healy A, Ruppert ES. Participation by pediatricians in early intervention: impetus from public law 99-457. Pediatrics 1992; 89: 98102.
  • 42
    Simpson GA, Colpe L, Greenspan S. Measuring functional developmental delay in infants and young children: prevalence rates from the NHIS-D. Paediatr Perinat Epidemiol 2003; 17: 6880.
  • 43
    American Academy of Pediatrics Committee on Children with Disabilities. Screening infants and young children for developmental disabilities. Pediatrics 1994; 93: 8635.